Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD
The novel immunoassay for the CSF Aβ-PF indicates that soluble Aβ-PF is quantifiable in human CSF in vivo. Increase in total (free and bound) CSF Aβ-PF with lecanemab-treatment is consistent with binding of Aβ-PF to lecanemab (target engagement), and mobilization of Aβ-PF from amyloid plaques (pharmacodynamic effect), confirming the unique dual mechanism of lecanemab targeting toxic Aβ-PF and plaques.
Authors
- Michio Kanekiyo
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Steven M. Hersch (ORCID: https://orcid.org/0000-0001-5948-6672)
- Kazuhiro Tahara (ORCID: https://orcid.org/0009-0000-4899-9990)
- Kanta Horie (ORCID: https://orcid.org/0000-0001-7736-2614)
- Akihiko Koyama (ORCID: https://orcid.org/0000-0002-3775-4629)
- Lynn D. Kramer
- Kazuyoshi Shuta
- Michael C. Irizarry
- Larisa Reyderman
- Pallavi Sachdev
Institutions
- Eisai (United States) (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108918
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00